{
    "eid": "2-s2.0-85069637118",
    "title": "Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection",
    "cover-date": "2019-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "BRAF V600E",
        "CD123",
        "Dual immunohistochemistry",
        "IDH1",
        "LEF1",
        "Multiplex immunohistochemistry",
        "Mutation-specific antibody",
        "PAX5",
        "TCF4"
    ],
    "authors": [
        "Narittee Sukswai",
        "Joseph D. Khoury"
    ],
    "citedby-count": 33,
    "ref-count": 83,
    "ref-list": [
        "Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial",
        "TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis",
        "Characterization of IDH1 p.R132H mutant clones using mutation-specific antibody in myeloid neoplasms",
        "Immunological properties of an antibody containing a fluorescent group",
        "An exaltation of experts: concerted efforts in the standardization of immunohistochemistry",
        "Continuous cultures of fused cells secreting antibody of predefined specificity",
        "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)",
        "T cell activation",
        "Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy",
        "Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype",
        "Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation",
        "Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?",
        "Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia",
        "Angioimmunoblastic T-cell lymphoma",
        "Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma",
        "Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma",
        "CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature",
        "Clinicopathologic features of B-cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases",
        "Diagnostic uses of Pax5 immunohistochemistry",
        "CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes",
        "Diagnostic algorithm of common mature B-cell lymphomas by immunohistochemistry",
        "Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH",
        "Cytogenetic findings in blastoid mantle cell lymphoma",
        "Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fine-needle aspiration biopsy",
        "CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases",
        "LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma",
        "Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas",
        "Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression",
        "Blastic plasmacytoid dendritic cell neoplasm",
        "CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia",
        "The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes",
        "Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies",
        "Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia",
        "CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value",
        "TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow",
        "Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development",
        "The multifaceted biology of plasmacytoid dendritic cells",
        "A Druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm",
        "Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms",
        "Minireview: cyclin D1: normal and abnormal functions",
        "Immunohistological recognition of cyclin D1 expression by non-lymphoid cells among lymphoid neoplastic cells",
        "Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma",
        "Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels",
        "The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study",
        "Chance identification of synchronous hairy cell leukemia and plasma cell myeloma in a potential HSC donor",
        "Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry",
        "New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma",
        "The role of IDH mutations in acute myeloid leukemia",
        "Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas",
        "Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features",
        "IDH mutations in cancer and progress toward development of targeted therapeutics",
        "Clinical implications of novel mutations in epigenetic modifiers in AML",
        "Monoclonal antibody specific for IDH1 R132H mutation",
        "A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation",
        "Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations",
        "SOHO state of the art update and next questions: IDH therapeutic targeting in AML",
        "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF",
        "Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling",
        "BRAF V600E mutation-specific antibody: a review",
        "Immunohistochemistry for BRAF V600E in the differential diagnosis of hairy cell leukemia vs other splenic B-cell lymphomas",
        "BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS",
        "Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations",
        "Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease",
        "Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience",
        "Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence",
        "Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody",
        "Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas",
        "Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature",
        "Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases",
        "Comparison of immunohistochemistry and direct sequencing methods for identification of the BRAF(V600E) mutation in papillary thyroid carcinoma",
        "Comparison of immunohistochemistry and direct Sanger sequencing for detection of the BRAF(V600E) mutation in thyroid neoplasm",
        "Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma",
        "Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma",
        "BRAF immunohistochemistry using clone VE1 is strongly concordant with BRAF(V600E) mutation test in papillary thyroid carcinoma",
        "Diagnostic and predictive immunohistochemistry for non-small cell lung carcinomas",
        "BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry",
        "The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort",
        "BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma",
        "Assessment of BRAF V600E status in colorectal carcinoma: tissue-specific discordances between immunohistochemistry and sequencing",
        "Utility of BRAF V600E immunohistochemistry expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Houston",
            "@id": "60015023",
            "affilname": "The University of Texas MD Anderson Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015023",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}